PMID- 15908091
OWN - NLM
STAT- MEDLINE
DCOM- 20050826
LR  - 20171116
IS  - 0278-5846 (Print)
IS  - 0278-5846 (Linking)
VI  - 29
IP  - 5
DP  - 2005 Jun
TI  - Serotonin (1A) receptor involvement in acute 3,4-methylenedioxymethamphetamine 
      (MDMA) facilitation of social interaction in the rat.
PG  - 648-57
AB  - The current study assessed whether various co-administered serotonin (5-HT) 
      receptor antagonists could prevent some of the acute behavioral effects of 
      3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") in rats. In the social 
      interaction test, MDMA (5 mg/kg) significantly increased the duration of total 
      social interaction between two conspecifics meeting for the first time. 
      Microanalysis showed that MDMA increased adjacent lying and approach behaviours 
      while reducing anogenital sniffing. MDMA (5 mg/kg) also caused elements of the 
      serotonin syndrome including low body posture and piloerection. In the emergence 
      test, MDMA significantly increased hide time and emergence latency indicating 
      increased anxiety-like behavior. Pretreatment with the 5HT 1A receptor 
      antagonist, WAY 100635 (1 mg/kg), prevented MDMA-induced increases in social 
      interaction and markers of the serotonin syndrome while the 5-HT 1B receptor 
      antagonist GR 55562 (1 mg/kg) and 5-HT 2A receptor antagonist ketanserin (1 
      mg/kg) were ineffective. The 5-HT 2B/2C receptor antagonist, SB 206553 (2 mg/kg), 
      prevented MDMA-induced prosocial effects but caused pronounced thigmotaxis 
      (hyperactivity at the periphery of the testing chamber). The anxiogenic effect of 
      MDMA on the emergence test was not prevented by pretreatment with any of the 5-HT 
      receptor antagonists tested. These results indicate that prosocial effect of MDMA 
      may involve 5-HT 1A and possibly 5-HT 2B/2C receptors. In contrast, MDMA-induced 
      generalised anxiety, as measured by the emergence test, seems unlikely to involve 
      the 5-HT 1A, 5-HT 1B or 5-HT 2A, 5-HT 2B or 5-HT 2C receptors.
FAU - Morley, Kirsten C
AU  - Morley KC
AD  - School of Psychology, University of Sydney, NSW 2006, Australia.
FAU - Arnold, Jonathon C
AU  - Arnold JC
FAU - McGregor, Iain S
AU  - McGregor IS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Prog Neuropsychopharmacol Biol Psychiatry
JT  - Progress in neuro-psychopharmacology & biological psychiatry
JID - 8211617
RN  - 0 (Hallucinogens)
RN  - 0 (Indoles)
RN  - 0 (Piperazines)
RN  - 0 (Pyridines)
RN  - 0 (Serotonin Agents)
RN  - 0 (Serotonin Antagonists)
RN  - 112692-38-3 (Receptor, Serotonin, 5-HT1A)
RN  - 71IH826FEG 
      (N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide)
RN  - 97F9DE4CT4 (Ketanserin)
RN  - AL4387525T (SB 206553)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Animals
MH  - Hallucinogens/*pharmacology
MH  - Indoles/pharmacology
MH  - *Interpersonal Relations
MH  - Ketanserin/pharmacology
MH  - Male
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*pharmacology
MH  - Piperazines/pharmacology
MH  - Pyridines/pharmacology
MH  - Rats
MH  - Rats, Wistar
MH  - Receptor, Serotonin, 5-HT1A/*drug effects
MH  - Serotonin Agents/*pharmacology
MH  - Serotonin Antagonists/pharmacology
MH  - Serotonin Syndrome/psychology
EDAT- 2005/05/24 09:00
MHDA- 2005/08/27 09:00
CRDT- 2005/05/24 09:00
PHST- 2005/04/06 00:00 [accepted]
PHST- 2005/05/24 09:00 [pubmed]
PHST- 2005/08/27 09:00 [medline]
PHST- 2005/05/24 09:00 [entrez]
AID - S0278-5846(05)00128-4 [pii]
AID - 10.1016/j.pnpbp.2005.04.009 [doi]
PST - ppublish
SO  - Prog Neuropsychopharmacol Biol Psychiatry. 2005 Jun;29(5):648-57. doi: 
      10.1016/j.pnpbp.2005.04.009.